Pembrolizumab companion diagnostic - Dako/Merck

Drug Profile

Pembrolizumab companion diagnostic - Dako/Merck

Alternative Names: Lambrolizumab companion diagnostic - Dako/Merck; PD-L1 IHC 22C3 pharmDx

Latest Information Update: 18 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dako A/S; Merck & Co
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cervical cancer; Gastric cancer; Non-small cell lung cancer

Most Recent Events

  • 13 Jun 2018 Launched for Cervical cancer (Diagnosis) in USA (unspecified route)
  • 12 Jun 2018 Registered for Cervical cancer (Diagnosis) in USA (unspecified route)
  • 28 May 2018 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer(Diagnosis) in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top